Oxular develops targeted suprachoroidal delivery systems for retinal therapeutics, enabling precise treatment of sight-threatening retinal disorders. This approach improves patient outcomes by providing long-lasting, localized therapy that effectively controls disease activity.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FCFounders
Product
Problem
Current treatments for retinal disorders often fail to deliver therapeutics effectively to the targeted ocular tissues, leading to suboptimal control of disease activity and potentially limiting long-term vision preservation. Traditional methods may also result in uneven drug distribution and systemic side effects.
Solution
Oxular is developing targeted suprachoroidal delivery systems designed to improve the treatment of sight-threatening retinal disorders. Their approach aims to transform the treatment paradigm by providing safe and durable therapeutics precisely delivered to specific ocular tissues. This targeted delivery seeks to maximize drug concentration at the affected site while minimizing off-target exposure. By controlling disease activity more effectively, Oxular intends to improve patient vision and overall outcomes.
Target Audience
The primary target audience includes patients with sight-threatening retinal disorders and the ophthalmologists and retinal specialists who treat them.
Features
- Suprachoroidal delivery system for precise targeting of retinal tissues
- Development of durable therapeutics for long-lasting treatment effects
- Pipeline of differentiated products focused on high-value retinal indications